Get the Stockscreener App
3.3901
3.99%
0.1301
Briacell Therapeutics Corp stock is traded at $3.3901, with a volume of 320.12K.
It is up +3.99% in the last 24 hours and down -23.99% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$3.26
Open:
$3.22
24h Volume:
320.12K
Relative Volume:
0.24
Market Cap:
$19.42M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-3.8091
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
+10.42%
1M Performance:
-23.99%
6M Performance:
-77.00%
1Y Performance:
-85.79%
1-Day Range:
$3.17
$3.46
1-Week Range:
$3.00
$3.46
52-Week Range:
$2.814
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.395 | 23.11M | 0 | -16.60M | -23.48M | -0.89 |
|
ONC
Beone Medicines Ltd Adr
|
245.79 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.73 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.61 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.59 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
When (BCT) Moves Investors should Listen (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Corp - Baystreet.ca
Cardiol Therapeutics Inc. - Baystreet.ca
BriaCell Bria-OTS? Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor - marketscreener.com
BriaCell advances cancer treatment with Bria-OTS in clinical study - Investing.com
BriaCell Advances Bria-OTS in Cancer Immunotherapy with New Study Phase - TipRanks
BriaCell (BCTX): Advances in Cancer Treatment with Bria-OTS | BC - GuruFocus
BriaCell advances cancer treatment with Bria-OTS in clinical study By Investing.com - Investing.com India
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor | BCTX Stock News - GuruFocus
BriaCell (BCTX): Advances in Cancer Treatment with Bria-OTS | BCTX Stock News - GuruFocus
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety - GlobeNewswire
BriaCell's Breast Cancer Immunotherapy Shows Early Success: Patient's Lung Metastasis Completely Resolved - Stock Titan
(BCT) Advanced Equity Analysis (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell (BCTX) Showcases Promising Data at ASCO 2025 | BCTX Sto - GuruFocus
BriaCell Therapeutics Reports Promising Phase 2 Results for Metastatic Breast Cancer Treatment - TipRanks
BriaCell to Showcase Survival and Clinical Benefit Data at ASCO Meeting Next Week - marketscreener.com
BriaCell (BCTX) Showcases Promising Data at ASCO 2025 | BCTX Stock News - GuruFocus
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 - The Manila Times
‘Don’t Doubt UNH Yet,’ Top JPMorgan Analyst Defends UnitedHealth Stock amid Recent Volatility - The Globe and Mail
Breakthrough: BriaCell's New Breast Cancer Drug Shows 13.4-Month Survival Rate, Beating Standard Therapies - Stock Titan
OpenAI CEO Sam Altman Admits Even They Are ‘a Little Bit Scared’ of What They’re Building—But That’s a Good Thing - The Globe and Mail
Stock Market News Today, 5/22/25 – Futures Flat, Post Deficit-Fear-Driven Sell-Off - The Globe and Mail
Moderna Stock Looks Ripe for a Short Squeeze - The Globe and Mail
(BCT) Trading Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell CEO Letter to Shareholders | BCTX Stock News - GuruFocus
BriaCell (BCTX) Reports Promising Advances in Cancer Treatment Studies | BCTX Stock News - GuruFocus
BriaCell Therapeutics Advances in Cancer Immunotherapy with Promising Clinical Results - TipRanks
Briacell Therapeutics CorpBria-Imt Receives FDA Fast Track Designation For Phase 3 Study - marketscreener.com
BriaCell CEO Letter to Shareholders - GlobeNewswire
Clinical Trial Breakthrough: BriaCell's Breast Cancer Therapy Shows 83% Success Rate, Surpassing Current Standard - Stock Titan
Public market insider buying at CGI (GIB) - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Stock Price Up 0.7% – Here’s Why - Defense World
BriaCell (BCTX) Reports Promising Advances in Cancer Treatment S - GuruFocus
Cisco Systems: A Safe Investment or a Stagnant Giant? - The Globe and Mail
(BCT) On The My Stocks Page (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics (CVE:BCT) Shares Down 3.8% – Here’s Why - Defense World
(BCT) Comprehensive Trading Strategy Report (BCT:CA) - news.stocktradersdaily.com
WonderFi Jumps Over 35% on Robinhood Acquisition News - The Globe and Mail
HighPeak Energy, Inc. Announces First Quarter 2025 Financial and Operating Results - The Globe and Mail
(BCT) Risk-Controlled Trading Report (BCT:CA) - news.stocktradersdaily.com
Why Are Investors Talking About Roblox Stock? - The Globe and Mail
(BCT) Trading Advice (BCT:CA) - news.stocktradersdaily.com
2 Cash-Producing Stocks to Keep an Eye On and 1 to Avoid - The Globe and Mail
(BCT) Investment Performance Report (BCT:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - PR Newswire
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Br - GuruFocus
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
How To Trade (BCT) (BCT:CA) - news.stocktradersdaily.com
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):